NCT00422903 - Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

1500 mg administered orally daily

DRUG

letrozole

2.5 mg administered orally daily

OTHER

placebo

1500 mg administered orally daily

Trial Locations (14)

21100

GSK Investigational Site, Varese

24047

GSK Investigational Site, Treviglio (BG)

26100

GSK Investigational Site, Cremona

29100

GSK Investigational Site, Piacenza

41012

GSK Investigational Site, Carpi (MO)

41100

GSK Investigational Site, Modena

42100

GSK Investigational Site, Reggio Emilia

47100

GSK Investigational Site, Forlì

47900

GSK Investigational Site, Rimini

56126

GSK Investigational Site, Pisa

66100

GSK Investigational Site, Chieti

72100

GSK Investigational Site, Brindisi

06156

GSK Investigational Site, Perugia

08916

GSK Investigational Site, Badalona